Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the body鈥檚 natural defence mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.
Highlights
The global Mucosolvan (Ambroxol) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Mucosolvan (Ambroxol) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Mucosolvan (Ambroxol) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Mucosolvan (Ambroxol) in Acute And Chronic Bronchitis is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Mucosolvan (Ambroxol) include Zywie LLC, Sanofi, Hanmi, Adare Pharma, Boehringer Ingelheim, Teijin, Astellas Pharma, Chiesi and Sidus, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Mucosolvan (Ambroxol), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mucosolvan (Ambroxol).
The Mucosolvan (Ambroxol) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Mucosolvan (Ambroxol) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mucosolvan (Ambroxol) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Zywie LLC
Sanofi
Hanmi
Adare Pharma
Boehringer Ingelheim
Teijin
Astellas Pharma
Chiesi
Sidus
Takeda
Euderma
Changzhou Siyao Pharmaceuticals
Shandong Fangming Pharmaceutical Group
TIPR Pharmaceutical
Hainan Weikang Pharmaceutical
Sandoz (Novartis)
Sinopharm
Jiangsu Hengrui Pharmaceutical
Yantai Dongcheng Dayang Pharmaceutical
Zhuhai Tongyuan Pharmaceutical
Beijing Taiyang Pharmaceutical
Nanjing Yihua Pharmaceutical
Shandong Luoxin Pharmaceutical Group
Shandong Yuxin Pharmaceutical
CSPC
Shanxi Qianyuan Pharmaceutical Group
Yangtze Pharmaceutical Group
Jiangsu Aosaikang Pharmaceutical
Jiangsu Haosen Pharmaceutical Group
Shenyang Xinma Pharmaceutical
Segment by Type
Tablets
Capsules
Injections
Solutions
Syrups
Granules
Segment by Application
Acute And Chronic Bronchitis
Bronchial Asthma
Bronchiectasis
Emphysema
Tuberculosis (TB)
Pneumoconiosis
Postoperative Medication
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mucosolvan (Ambroxol) companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Mucosolvan (Ambroxol) 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Tablets
1.2.3 Capsules
1.2.4 Injections
1.2.5 Solutions
1.2.6 Syrups
1.2.7 Granules
1.3 麻豆原创 by Application
1.3.1 Global Mucosolvan (Ambroxol) 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Acute And Chronic Bronchitis
1.3.3 Bronchial Asthma
1.3.4 Bronchiectasis
1.3.5 Emphysema
1.3.6 Tuberculosis (TB)
1.3.7 Pneumoconiosis
1.3.8 Postoperative Medication
1.3.9 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mucosolvan (Ambroxol) 麻豆原创 Perspective (2018-2029)
2.2 Mucosolvan (Ambroxol) Growth Trends by Region
2.2.1 Global Mucosolvan (Ambroxol) 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Mucosolvan (Ambroxol) Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Mucosolvan (Ambroxol) Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Mucosolvan (Ambroxol) 麻豆原创 Dynamics
2.3.1 Mucosolvan (Ambroxol) Industry Trends
2.3.2 Mucosolvan (Ambroxol) 麻豆原创 Drivers
2.3.3 Mucosolvan (Ambroxol) 麻豆原创 Challenges
2.3.4 Mucosolvan (Ambroxol) 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mucosolvan (Ambroxol) Players by Revenue
3.1.1 Global Top Mucosolvan (Ambroxol) Players by Revenue (2018-2023)
3.1.2 Global Mucosolvan (Ambroxol) Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Mucosolvan (Ambroxol) 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Mucosolvan (Ambroxol) Revenue
3.4 Global Mucosolvan (Ambroxol) 麻豆原创 Concentration Ratio
3.4.1 Global Mucosolvan (Ambroxol) 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mucosolvan (Ambroxol) Revenue in 2022
3.5 Mucosolvan (Ambroxol) Key Players Head office and Area Served
3.6 Key Players Mucosolvan (Ambroxol) Product Solution and Service
3.7 Date of Enter into Mucosolvan (Ambroxol) 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Mucosolvan (Ambroxol) Breakdown Data by Type
4.1 Global Mucosolvan (Ambroxol) Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Mucosolvan (Ambroxol) Forecasted 麻豆原创 Size by Type (2024-2029)
5 Mucosolvan (Ambroxol) Breakdown Data by Application
5.1 Global Mucosolvan (Ambroxol) Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Mucosolvan (Ambroxol) Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Mucosolvan (Ambroxol) 麻豆原创 Size (2018-2029)
6.2 North America Mucosolvan (Ambroxol) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Mucosolvan (Ambroxol) 麻豆原创 Size by Country (2018-2023)
6.4 North America Mucosolvan (Ambroxol) 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mucosolvan (Ambroxol) 麻豆原创 Size (2018-2029)
7.2 Europe Mucosolvan (Ambroxol) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Mucosolvan (Ambroxol) 麻豆原创 Size by Country (2018-2023)
7.4 Europe Mucosolvan (Ambroxol) 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mucosolvan (Ambroxol) 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Mucosolvan (Ambroxol) 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Mucosolvan (Ambroxol) 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Mucosolvan (Ambroxol) 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mucosolvan (Ambroxol) 麻豆原创 Size (2018-2029)
9.2 Latin America Mucosolvan (Ambroxol) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Mucosolvan (Ambroxol) 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Mucosolvan (Ambroxol) 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mucosolvan (Ambroxol) 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Mucosolvan (Ambroxol) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Mucosolvan (Ambroxol) 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Mucosolvan (Ambroxol) 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Zywie LLC
11.1.1 Zywie LLC Company Detail
11.1.2 Zywie LLC Business Overview
11.1.3 Zywie LLC Mucosolvan (Ambroxol) Introduction
11.1.4 Zywie LLC Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.1.5 Zywie LLC Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Mucosolvan (Ambroxol) Introduction
11.2.4 Sanofi Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.2.5 Sanofi Recent Development
11.3 Hanmi
11.3.1 Hanmi Company Detail
11.3.2 Hanmi Business Overview
11.3.3 Hanmi Mucosolvan (Ambroxol) Introduction
11.3.4 Hanmi Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.3.5 Hanmi Recent Development
11.4 Adare Pharma
11.4.1 Adare Pharma Company Detail
11.4.2 Adare Pharma Business Overview
11.4.3 Adare Pharma Mucosolvan (Ambroxol) Introduction
11.4.4 Adare Pharma Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.4.5 Adare Pharma Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Detail
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Mucosolvan (Ambroxol) Introduction
11.5.4 Boehringer Ingelheim Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Teijin
11.6.1 Teijin Company Detail
11.6.2 Teijin Business Overview
11.6.3 Teijin Mucosolvan (Ambroxol) Introduction
11.6.4 Teijin Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.6.5 Teijin Recent Development
11.7 Astellas Pharma
11.7.1 Astellas Pharma Company Detail
11.7.2 Astellas Pharma Business Overview
11.7.3 Astellas Pharma Mucosolvan (Ambroxol) Introduction
11.7.4 Astellas Pharma Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.7.5 Astellas Pharma Recent Development
11.8 Chiesi
11.8.1 Chiesi Company Detail
11.8.2 Chiesi Business Overview
11.8.3 Chiesi Mucosolvan (Ambroxol) Introduction
11.8.4 Chiesi Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.8.5 Chiesi Recent Development
11.9 Sidus
11.9.1 Sidus Company Detail
11.9.2 Sidus Business Overview
11.9.3 Sidus Mucosolvan (Ambroxol) Introduction
11.9.4 Sidus Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.9.5 Sidus Recent Development
11.10 Takeda
11.10.1 Takeda Company Detail
11.10.2 Takeda Business Overview
11.10.3 Takeda Mucosolvan (Ambroxol) Introduction
11.10.4 Takeda Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.10.5 Takeda Recent Development
11.11 Euderma
11.11.1 Euderma Company Detail
11.11.2 Euderma Business Overview
11.11.3 Euderma Mucosolvan (Ambroxol) Introduction
11.11.4 Euderma Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.11.5 Euderma Recent Development
11.12 Changzhou Siyao Pharmaceuticals
11.12.1 Changzhou Siyao Pharmaceuticals Company Detail
11.12.2 Changzhou Siyao Pharmaceuticals Business Overview
11.12.3 Changzhou Siyao Pharmaceuticals Mucosolvan (Ambroxol) Introduction
11.12.4 Changzhou Siyao Pharmaceuticals Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.12.5 Changzhou Siyao Pharmaceuticals Recent Development
11.13 Shandong Fangming Pharmaceutical Group
11.13.1 Shandong Fangming Pharmaceutical Group Company Detail
11.13.2 Shandong Fangming Pharmaceutical Group Business Overview
11.13.3 Shandong Fangming Pharmaceutical Group Mucosolvan (Ambroxol) Introduction
11.13.4 Shandong Fangming Pharmaceutical Group Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.13.5 Shandong Fangming Pharmaceutical Group Recent Development
11.14 TIPR Pharmaceutical
11.14.1 TIPR Pharmaceutical Company Detail
11.14.2 TIPR Pharmaceutical Business Overview
11.14.3 TIPR Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.14.4 TIPR Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.14.5 TIPR Pharmaceutical Recent Development
11.15 Hainan Weikang Pharmaceutical
11.15.1 Hainan Weikang Pharmaceutical Company Detail
11.15.2 Hainan Weikang Pharmaceutical Business Overview
11.15.3 Hainan Weikang Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.15.4 Hainan Weikang Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.15.5 Hainan Weikang Pharmaceutical Recent Development
11.16 Sandoz (Novartis)
11.16.1 Sandoz (Novartis) Company Detail
11.16.2 Sandoz (Novartis) Business Overview
11.16.3 Sandoz (Novartis) Mucosolvan (Ambroxol) Introduction
11.16.4 Sandoz (Novartis) Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.16.5 Sandoz (Novartis) Recent Development
11.17 Sinopharm
11.17.1 Sinopharm Company Detail
11.17.2 Sinopharm Business Overview
11.17.3 Sinopharm Mucosolvan (Ambroxol) Introduction
11.17.4 Sinopharm Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.17.5 Sinopharm Recent Development
11.18 Jiangsu Hengrui Pharmaceutical
11.18.1 Jiangsu Hengrui Pharmaceutical Company Detail
11.18.2 Jiangsu Hengrui Pharmaceutical Business Overview
11.18.3 Jiangsu Hengrui Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.18.4 Jiangsu Hengrui Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.18.5 Jiangsu Hengrui Pharmaceutical Recent Development
11.19 Yantai Dongcheng Dayang Pharmaceutical
11.19.1 Yantai Dongcheng Dayang Pharmaceutical Company Detail
11.19.2 Yantai Dongcheng Dayang Pharmaceutical Business Overview
11.19.3 Yantai Dongcheng Dayang Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.19.4 Yantai Dongcheng Dayang Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.19.5 Yantai Dongcheng Dayang Pharmaceutical Recent Development
11.20 Zhuhai Tongyuan Pharmaceutical
11.20.1 Zhuhai Tongyuan Pharmaceutical Company Detail
11.20.2 Zhuhai Tongyuan Pharmaceutical Business Overview
11.20.3 Zhuhai Tongyuan Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.20.4 Zhuhai Tongyuan Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.20.5 Zhuhai Tongyuan Pharmaceutical Recent Development
11.21 Beijing Taiyang Pharmaceutical
11.21.1 Beijing Taiyang Pharmaceutical Company Detail
11.21.2 Beijing Taiyang Pharmaceutical Business Overview
11.21.3 Beijing Taiyang Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.21.4 Beijing Taiyang Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.21.5 Beijing Taiyang Pharmaceutical Recent Development
11.22 Nanjing Yihua Pharmaceutical
11.22.1 Nanjing Yihua Pharmaceutical Company Detail
11.22.2 Nanjing Yihua Pharmaceutical Business Overview
11.22.3 Nanjing Yihua Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.22.4 Nanjing Yihua Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.22.5 Nanjing Yihua Pharmaceutical Recent Development
11.23 Shandong Luoxin Pharmaceutical Group
11.23.1 Shandong Luoxin Pharmaceutical Group Company Detail
11.23.2 Shandong Luoxin Pharmaceutical Group Business Overview
11.23.3 Shandong Luoxin Pharmaceutical Group Mucosolvan (Ambroxol) Introduction
11.23.4 Shandong Luoxin Pharmaceutical Group Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.23.5 Shandong Luoxin Pharmaceutical Group Recent Development
11.24 Shandong Yuxin Pharmaceutical
11.24.1 Shandong Yuxin Pharmaceutical Company Detail
11.24.2 Shandong Yuxin Pharmaceutical Business Overview
11.24.3 Shandong Yuxin Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.24.4 Shandong Yuxin Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.24.5 Shandong Yuxin Pharmaceutical Recent Development
11.25 CSPC
11.25.1 CSPC Company Detail
11.25.2 CSPC Business Overview
11.25.3 CSPC Mucosolvan (Ambroxol) Introduction
11.25.4 CSPC Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.25.5 CSPC Recent Development
11.26 Shanxi Qianyuan Pharmaceutical Group
11.26.1 Shanxi Qianyuan Pharmaceutical Group Company Detail
11.26.2 Shanxi Qianyuan Pharmaceutical Group Business Overview
11.26.3 Shanxi Qianyuan Pharmaceutical Group Mucosolvan (Ambroxol) Introduction
11.26.4 Shanxi Qianyuan Pharmaceutical Group Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.26.5 Shanxi Qianyuan Pharmaceutical Group Recent Development
11.27 Yangtze Pharmaceutical Group
11.27.1 Yangtze Pharmaceutical Group Company Detail
11.27.2 Yangtze Pharmaceutical Group Business Overview
11.27.3 Yangtze Pharmaceutical Group Mucosolvan (Ambroxol) Introduction
11.27.4 Yangtze Pharmaceutical Group Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.27.5 Yangtze Pharmaceutical Group Recent Development
11.28 Jiangsu Aosaikang Pharmaceutical
11.28.1 Jiangsu Aosaikang Pharmaceutical Company Detail
11.28.2 Jiangsu Aosaikang Pharmaceutical Business Overview
11.28.3 Jiangsu Aosaikang Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.28.4 Jiangsu Aosaikang Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.28.5 Jiangsu Aosaikang Pharmaceutical Recent Development
11.29 Jiangsu Haosen Pharmaceutical Group
11.29.1 Jiangsu Haosen Pharmaceutical Group Company Detail
11.29.2 Jiangsu Haosen Pharmaceutical Group Business Overview
11.29.3 Jiangsu Haosen Pharmaceutical Group Mucosolvan (Ambroxol) Introduction
11.29.4 Jiangsu Haosen Pharmaceutical Group Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.29.5 Jiangsu Haosen Pharmaceutical Group Recent Development
11.30 Shenyang Xinma Pharmaceutical
11.30.1 Shenyang Xinma Pharmaceutical Company Detail
11.30.2 Shenyang Xinma Pharmaceutical Business Overview
11.30.3 Shenyang Xinma Pharmaceutical Mucosolvan (Ambroxol) Introduction
11.30.4 Shenyang Xinma Pharmaceutical Revenue in Mucosolvan (Ambroxol) Business (2018-2023)
11.30.5 Shenyang Xinma Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Zywie LLC
Sanofi
Hanmi
Adare Pharma
Boehringer Ingelheim
Teijin
Astellas Pharma
Chiesi
Sidus
Takeda
Euderma
Changzhou Siyao Pharmaceuticals
Shandong Fangming Pharmaceutical Group
TIPR Pharmaceutical
Hainan Weikang Pharmaceutical
Sandoz (Novartis)
Sinopharm
Jiangsu Hengrui Pharmaceutical
Yantai Dongcheng Dayang Pharmaceutical
Zhuhai Tongyuan Pharmaceutical
Beijing Taiyang Pharmaceutical
Nanjing Yihua Pharmaceutical
Shandong Luoxin Pharmaceutical Group
Shandong Yuxin Pharmaceutical
CSPC
Shanxi Qianyuan Pharmaceutical Group
Yangtze Pharmaceutical Group
Jiangsu Aosaikang Pharmaceutical
Jiangsu Haosen Pharmaceutical Group
Shenyang Xinma Pharmaceutical
听
听
*If Applicable.
